Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a report issued on Friday.

Separately, HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS traded down $0.13 on Friday, hitting $2.05. 736,031 shares of the stock were exchanged, compared to its average volume of 1,001,223. Aclaris Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.72. The stock has a market capitalization of $146.43 million, a price-to-earnings ratio of -3.94 and a beta of 0.10. The company’s 50-day moving average price is $1.49 and its 200 day moving average price is $1.30.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The business had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. As a group, equities research analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Aclaris Therapeutics during the 1st quarter worth $39,000. SG Americas Securities LLC grew its holdings in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after buying an additional 13,461 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 61,602 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aclaris Therapeutics during the 2nd quarter worth about $119,000. Finally, Assenagon Asset Management S.A. bought a new position in Aclaris Therapeutics in the third quarter valued at approximately $214,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.